LadRx's EBITDA per Share for the
three
months ended in Dec. 2023 was $-1.78.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of LadRx was 66.40% per year. The lowest was -113.80% per year. And the median was 13.50% per year.
Competitive Comparison of LadRx's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, LadRx's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LadRx's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LadRx's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where LadRx's 5-Year EBITDA Growth Rate falls into.
LadRx 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
LadRx 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of LadRx's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LADX has been successfully added to your